FABRICATION OF A PROTOTYPE IMPLANTABLE GLUCOSE SENSOR

Information

  • Research Project
  • 2645410
  • ApplicationId
    2645410
  • Core Project Number
    R43DK054097
  • Full Project Number
    1R43DK054097-01
  • Serial Number
    54097
  • FOA Number
  • Sub Project Id
  • Project Start Date
    8/31/1998 - 26 years ago
  • Project End Date
    1/31/2000 - 25 years ago
  • Program Officer Name
    HARMON, JOAN T.
  • Budget Start Date
    8/31/1998 - 26 years ago
  • Budget End Date
    1/31/2000 - 25 years ago
  • Fiscal Year
    1998
  • Support Year
    1
  • Suffix
  • Award Notice Date
    8/30/1998 - 26 years ago
Organizations

FABRICATION OF A PROTOTYPE IMPLANTABLE GLUCOSE SENSOR

There is a well-known need for an implantable glucose sensor in the treatment of diabetes. A continuous sensor would provide users a warning of hypoglycemia and information for improved insulin replacement either by conventional injection, mechanical insulin pumps or other means. We have a sensor that shows promise. The sensor employs immobilized glucose oxidase coupled to a potentiostatic oxygen electrode, operated in conjunction with an oxygen reference electrode. The sensor was developed over the last fifteen years using a systematic engineering approach. A simple version of the sensor has been employed as a central venous implant in dogs and has functioned for more that 100 days without the need for recalibration, the standing published record for long-term performance. The sensor has clear potential for operation as an implant for longer periods. However, in many cases, especially in children, a tissue site may be preferable for implantation. GlySens' goal is to produce a different type of glucose sensor for application in tissues. In this Phase I project we plan to: (1) make a prototype sensor based on adaptation of integrated circuit fabrication technology; (2) fabricate and validate prototype benchtop instrumentation to operate the sensor; and (3) characterize and test the sensor extensively in vitro. These studies will identify factors that affect sensor performance and lifetime. This work represents innovation over our previous sensor design and fabrication methods and is a necessary step toward commercial application. In Phase II, the sensor will be refined if necessary. PROPOSED COMMERCIAL APPLICATION: The management of diabetes consumes 15% of total national health care expenditures, 25% of MediCare expenditures, ad is responsible for an enormous, untold cost in human resources. These costs could be reduced substantially by better blood glucose control resulting from improved insulin replacement, made possible by continuous monitoring of blood glucose. There are several million people with diabetes who could benefit.

IC Name
NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES
  • Activity
    R43
  • Administering IC
    DK
  • Application Type
    1
  • Direct Cost Amount
  • Indirect Cost Amount
  • Total Cost
  • Sub Project Total Cost
  • ARRA Funded
  • CFDA Code
    847
  • Ed Inst. Type
  • Funding ICs
  • Funding Mechanism
  • Study Section
    ZRG7
  • Study Section Name
  • Organization Name
    GLYSENS, INC.
  • Organization Department
  • Organization DUNS
    070731646
  • Organization City
    SAN DIEGO
  • Organization State
    CA
  • Organization Country
    UNITED STATES
  • Organization Zip Code
    92121
  • Organization District
    UNITED STATES